Last reviewed · How we verify
NCT07011888
Innovative Physiotherapy in Stroke Rehabilitation
NA trial testing SaeboStim GO with Saebo Glove Rehabilitation Program in Stroke, Ischemic in 1 participant. Not yet recruiting.
30 December 2025
Quick facts
| Lead sponsor | Sevval Yesilkır |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 15 November 2025 |
| Primary completion | 30 December 2025 |
| Estimated completion | 30 January 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- SaeboStim GO with Saebo Glove Rehabilitation Program
Conditions studied
- Stroke, Ischemic — all drugs for Stroke, Ischemic →
- Chronic Stroke Survivors — all drugs for Chronic Stroke Survivors →
Sponsor
Sevval Yesilkır
Who can join
Adults 50 to 50, male only, with Stroke, Ischemic or Chronic Stroke Survivors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study reports a single-case rehabilitation program for a chronic stroke patient focusing on innovative physiotherapy techniques. Over six weeks, the patient will undergo combined treatments including vestibular rehabilitation therapy, ultrasound therapy, and functional hand therapy using Saebo devices. The goal is to improve motor functions and daily living independence. This report aims to share clinical insights and outcomes to support stroke rehabilitation practices.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07011888
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stroke, Ischemic
Currently open trials in the same condition.
- NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
- NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
- NCT07282041 — Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis · Phase 2, PHASE3 · recruiting
- NCT07135089 — Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban · Phase 3 · recruiting
- NCT07047014 — Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ische · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07011888 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sevval Yesilkır
- Last refreshed: 1 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07011888.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing